LSD

Lysergic acid diethylamide (LSD), the prototypical serotonergic psychedelic and the most pharmacologically potent member of the ergoline class, is a semisynthetic derivative of lysergic acid originally synthesized at the Sandoz Forschungsinstitut in Basel in 1938 by Albert Hofmann and recharacterized as a profoundly psychoactive agent in 1943 following Hofmann's accidental self-exposure and subsequent deliberate self-administration. LSD acts primarily as a partial agonist at the serotonin 5-HT2A receptor, the molecular target now established as necessary and sufficient for the characteristic psychedelic phenomenology, while simultaneously engaging 5-HT1A, 5-HT2C, 5-HT6, 5-HT7, dopamine D1 and D2, and trace amine-associated receptor 1 (TAAR1) at pharmacologically relevant concentrations. The compound is distinguished from other serotonergic psychedelics by its exceptional potency (threshold activity at approximately 20 to 25 micrograms oral), its prolonged duration of action (8 to 12 hours of subjective effects from a single oral dose), and the structural basis for both characteristics: a crystallographic "lid" formed by extracellular loop 2 of the 5-HT2A receptor that traps LSD in the orthosteric binding pocket and produces anomalously slow dissociation kinetics relative to other tryptamine and phenethylamine agonists.

Pharmacokinetics in humans are well characterized from modern controlled studies at the University of Basel. Oral bioavailability is approximately 71 percent. Maximum plasma concentrations are reached 1.5 to 2 hours after oral administration, with a Cmax of approximately 1.7 ng/mL after 100 micrograms. Plasma concentrations decline with first-order kinetics and an initial half-life of approximately 3.6 hours, with slower terminal elimination yielding an effective half-life of approximately 8.9 hours. Metabolism is hepatic, involving CYP2D6, CYP3A4, CYP1A2, CYP2C9, and CYP2E1. The principal metabolite is 2-oxo-3-hydroxy-LSD (O-H-LSD), which is pharmacologically inactive and is detected in urine at 4 to 40 times the concentration of unchanged LSD. N-demethylation produces nor-LSD as a minor metabolite. CYP2D6 poor metabolizers exhibit approximately 75 percent higher area-under-the-curve and prolonged elimination, a polymorphic phenotype with implications for dose-response variability in clinical research.

The clinical research record spans three distinct eras: the initial 1950s through 1960s therapeutic exploration, during which an estimated 40,000 patients received LSD under clinical supervision for indications including alcoholism, depression, and anxiety associated with terminal illness; the regulatory prohibition era (1966 through approximately 2006) during which clinical research essentially ceased following Schedule I classification in the United States and equivalent controls internationally; and the contemporary renaissance beginning with the Gasser et al. (2014) pilot trial of LSD-assisted psychotherapy for anxiety associated with life-threatening disease. The current clinical pipeline is anchored by MindMed's MM-120 (lysergide d-tartrate) program, which received United States Food and Drug Administration Breakthrough Therapy Designation in March 2024 for generalized anxiety disorder on the basis of Phase 2b results demonstrating a 65 percent clinical response rate and a 48 percent remission rate at 12 weeks following a single 100 microgram oral dose. Phase 3 pivotal trials in generalized anxiety disorder commenced in 2024, and a registrational program in major depressive disorder is planned. Additional clinical evidence supports efficacy in alcohol use disorder (Krebs and Johansen 2012 meta-analysis of six randomized controlled trials, odds ratio 1.96), anxiety with life-threatening illness (Gasser et al. 2014; Schmid et al. 2023), and depression (open-label microdosing trial reporting 59.5 percent MADRS reduction).

Safety in controlled clinical settings is favorable. Common acute effects are dose-dependent increases in heart rate (5 to 20 beats per minute) and blood pressure (10 to 20 mmHg systolic), with psychological adverse events including transient anxiety, perceptual disturbance, and emotional lability that are managed through the supervised therapeutic setting. No organ toxicity, no physical dependence, and no lethal dose in humans have been established. Hallucinogen-persisting perception disorder (HPPD) is a rare long-term risk, principally associated with repeated or high-dose unsupervised use. LSD is classified as Schedule I in the United States and is subject to equivalent controls in most jurisdictions. This monograph reviews the chemistry, synthesis, and stereochemistry of LSD; the multi-receptor pharmacology in molecular detail; the comprehensive human pharmacokinetic record including CYP2D6 polymorphism; the preclinical neuroplasticity evidence; the clinical evidence base across anxiety, depressive, substance use, and end-of-life indications; sourcing and quality considerations for research use; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five psychedelic or psychedelic-adjacent compounds (psilocybin, MDMA, DMT, ketamine, mescaline) against LSD on five competency standards.